Webinar series on neuroendocrine tumours

The Canadian Oncology Societies and the Canadian Association of Medical Oncologists continue the series of webcasts on Neuroendocrine Tumours by presenting an hour-long webinar by Dr. Walter Kocha, Dr. Amil Shah, and Dr. Peter Metrakos. This webinar is part two of a three-part series and will cover the subjects of Surgery, Cardiology, Radiology & Principals of Medical Management in Treatment.

The webinar series offers a venue to discuss interdisciplinary clinical issues and is aimed at all oncology professionals.

When: Wednesday November 4, 2009 at 12 noon Eastern Time Where: http://www.cos.ca or http://events.digitalmedia.telus.com/cos/110409/index.php For information: 877 990 9044

These programs are developed under the guidance of Dr. Charles Butts, Cross Cancer Institute President of CAMO; Dr. Amil Shah, BC Cancer Agency; Dr. Kiran Virik, Medical Oncologist, QEII HSC, Halifax, Dr. Benoit Samson, Hôpital Charles-Lemoyne, and Dr. Jean Maroun, Ottawa Regional Cancer Centre, with educational funding from Amgen, AstraZeneca, Novartis, Roche, and sanofi-aventis.

Source: CANADIAN ONCOLOGY SOCIETIES

Source:

CANADIAN ASSOCIATION OF MEDICAL ONCOLOGISTS

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation